| May. 07, 2008 | Print This | Email This |
| |
|
|
|
Interested parties may access the conference call by dialing (877) 407-4018 in the U.S. and Canada or (201) 689-8471 internationally. A telephonic replay will be available through May 20, 2008 by dialing (877) 660-6853 in the U.S. and Canada or (201) 612-7415 internationally (Account Number 3055 and Conference ID 284385).
About ImaRx Therapeutics
ImaRx Therapeutics is a biopharmaceutical company developing and commercializing therapies for vascular disorders. The Company's research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology. The Company's commercialization efforts are currently focused on its product, urokinase, for the treatment of acute massive pulmonary embolism.
Contacts: The Ruth Group (Investors/Media) Sara Ephraim/Jason Rando 646-536-7002 or 7025 sephraim@theruthgroup.com jrando@theruthgroup.com
ImaRx Therapeutics, Inc.CONTACT: Investors and Media: Sara Ephraim, sephraim@theruthgroup.com,
Jason Rando,
Ruth Group, for ImaRx Therapeutics, Inc.
Web site: http://www.imarx.com/

